Quick Answer
Seres Therapeutics, Inc. reported Revenue (ASC 606) of $7.13 million for fiscal year 2022.
Seres Therapeutics, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2022 | $7.13M | -95.0% |
| 2021 | $143.86M | +1109.2% |
| 2020 | $11.90M | -56.2% |
| 2019 | $27.19M | +1.0% |
| 2018 | $26.92M | -16.1% |
| 2017 | $32.10M | +47.5% |
| 2016 | $21.77M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2022 | $3.44M | -97.3% | +183.2% |
| June 30, 2022 | $1.22M | -76.9% | -18.6% |
| March 31, 2022 | $1.49M | -67.9% | -98.8% |
| September 30, 2021 | $126.72M | +158306.2% | +2307.8% |
| June 30, 2021 | $5.26M | +1.5% | +13.2% |
| March 31, 2021 | $4.65M | -14.9% | +5710.0% |
| September 30, 2020 | $80.0K | -98.3% | -98.5% |
| June 30, 2020 | $5.19M | -50.4% | -5.1% |
- Seres Therapeutics, Inc. showed a decrease of -95.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2022 period, Seres Therapeutics, Inc.’s revenue (asc 606) has declined by 67.3% (from $21.77 million to $7.13 million).
- The most recent figure is from Seres Therapeutics, Inc.’s fiscal year 2022 report (Form 10-K), filed with the SEC on March 7, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: